Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
6 evidence topics · 5 sources
U.S. women living with breast cancer, all stages
U.S. women living with metastatic breast cancer, 2013 and 2017
“In 2013, the last year with observed data, we estimate a prevalence of MBC of 138,622 of which 38,897 (28%) are survivors who were initially diagnosed with de novo stage IV disease and 99,725 (72%) survivors initially diagnosed with stage I–III BC who later progressed to MBC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We project that by 1/1/2017 there will be 154,794 women living with MBC in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. women living with metastatic breast cancer: duration since metastatic diagnosis
U.S. individuals living with metastatic female breast cancer, 2018 estimate and 2025 projection
| Measure | Breast (female) |
|---|---|
| Number living with metastatic disease on January 1, 2018, de novo (observed) | “54 117”View highlighted excerpt for this quote |
| Number living with metastatic disease on January 1, 2018, de novo and recurrence (estimated) | “140 230”View highlighted excerpt for this quote |
| Projected number living with metastatic disease (de novo and recurrence) on January 1, 2025 | “169 347”View highlighted excerpt for this quote |
“Almost 30% of individuals diagnosed with metastatic melanoma and one-fifth of individuals diagnosed with metastatic colorectal or metastatic breast cancer are estimated to have been living with metastatic disease for 10 or more years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of individuals living with metastatic cancer is projected to increase from 2019 to 2025 for breast, bladder, colorectal, and prostate cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. share of women living with metastatic disease first diagnosed at stage I to III
U.S. prevalence of previously treated ER-positive HER2-negative advanced disease
No evidence found.
Worldwide 5-year prevalence of breast cancer by continent, GLOBOCAN 2024
| Continent | 5-year prevalent cases | Percent |
|---|---|---|
| Asia | “3 291 849” | “40.3%” |
| Europe | “2 208 013” | “27.1%” |
| Northern America | “1 373 135” | “16.8%” |
| Latin America and the Caribbean | “670 478” | “8.2%” |
| Africa | “491 878” | “6.0%” |
| Oceania | “126 982” | “1.6%” |